Acurx Pharmaceuticals, Inc. — Investor Relations & Filings
Filings indexed
211
across all filing types
Latest filing
2026-05-12
Regulatory Filings
Country
US
United States of America
Listing
US
ACXP
Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of antibiotics. The company's therapeutic candidates are designed to treat infections caused by bacteria designated as priority pathogens by organizations such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC). Acurx's approach involves developing antibiotics that inhibit a novel molecular target previously unexploited in medical research. A primary focus of its clinical development is the treatment of Clostridioides difficile Infection (CDI).
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 424B3 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer) | 2026-05-12 | English | |
| 424B3 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer) | 2026-05-12 | English | |
| S-1 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer) | 2026-05-04 | English | |
| 8-K - Acurx Pharmaceuticals, Inc. (0001736243) (Filer) | 2026-04-16 | English | |
| 424B5 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer) | 2026-04-16 | English | |
| 424B3 Filing | 2026-02-11 | English |
Browse filings by year
9 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
8 filings
| |||||
| 45338325 | 424B3 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer) | 2026-05-12 | English | ||
| 45338260 | 424B3 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer) | 2026-05-12 | English | ||
| 41041919 | S-1 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer) | 2026-05-04 | English | ||
| 34647178 | 8-K - Acurx Pharmaceuticals, Inc. (0001736243) (Filer) | 2026-04-16 | English | ||
| 34647177 | 424B5 - Acurx Pharmaceuticals, Inc. (0001736243) (Filer) | 2026-04-16 | English | ||
| 31526040 | 424B3 Filing | 2026-02-11 | English | ||
| 31526014 | S-1 Filing | 2026-02-02 | English | ||
| 13101932 | Regulatory Filings 2026 | 2026-01-07 | English | ||
|
2025
7 filings
| |||||
| 13101933 | FORM S-3/A | 2025-12-30 | English | ||
| 13101935 | Major Shareholding Notification 2025 | 2025-11-15 | English | ||
| 13101934 | 10-Q | 2025-11-12 | English | ||
| 13101936 | 424B3 | 2025-11-10 | English | ||
| 13101937 | FORM S-1 | 2025-10-20 | English | ||
| 13101938 | FORM 8-K | 2025-09-22 | English | ||
| 13101939 | FORM 8-K | 2025-09-19 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Asymchem Laboratories (Tianjin) Co., Ltd.
Global CDMO providing integrated CMC services across the dr…
|
002821 | CN | Manufacturing |
|
ATAI Life Sciences N.V.
Develops psychedelic-inspired therapies for mental health d…
|
ATAI | NL | Manufacturing |
|
Atea Pharmaceuticals, Inc.
Clinical-stage biopharma developing oral antiviral therapie…
|
AVIR | US | Manufacturing |
|
Athira Pharma, Inc.
Biopharma firm developing small molecule therapeutics for n…
|
ATHA | US | Manufacturing |
|
Atlas Global Brands Inc.
Global cannabis company spanning cultivation, manufacturing…
|
ATL | CA | Manufacturing |
|
ATOSSA THERAPEUTICS, INC.
Clinical-stage biopharmaceutical company developing oncolog…
|
ATOS | US | Manufacturing |
|
Atrium Innovations Inc.
Develops, manufactures, and sells science-based natural hea…
|
ATB | CA | Manufacturing |
|
Atrium Therapeutics, Inc.
Pioneering precision RNA medicines for cardiac diseases, fo…
|
RNA | US | Manufacturing |
|
aTYR PHARMA INC
Develops medicines based on tRNA synthetase biology for fib…
|
ATYR | US | Manufacturing |
|
Aura Biosciences, Inc.
Develops Virus-Like Drug Conjugates as targeted therapies f…
|
AURA | US | Manufacturing |
Acurx Pharmaceuticals, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35349/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35349 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35349 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35349 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35349}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Acurx Pharmaceuticals, Inc. (id: 35349)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.